[Federal Register: December 24, 2002 (Volume 67, Number 247)]
[Notices]
[Page 78488-78489]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr24de02-117]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Methods and Compositions
for the Promotion of Hair Growth Utilizing Actin Binding Peptides
AGENCY: National Institutes of Health, Public Health Services, DHHS.
ACTION: None.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR
[[Page 78489]]
404.7(a)(1)(i), that the National Institutes of Health, Department of
Health and Human Services, is contemplating the grant of an exclusive
license to practice the invention embodied in U.S. provisional patent
application 60/351,386 (DHHS ref. no. E-053-2002/0-US-01) filed January
25, 2002, and entitled ``Methods and compositions for the promotion of
hair growth utilizing actin binding peptides,'' to Lee's Pharmaceutical
(Hong Kong) Ltd. having a place of business in Hong Kong. The patent
rights in this invention have been assigned to the United States of
America.
The prospective exclusive license territory will be China, Hong
Kong and Taiwan. The field of use may be limited to use of actin
binding peptides for the promotion of hair growth.
DATES: Only written comments and/or license applications which are
received by the National Institutes of Health on or before February 24,
2003, will be considered.
ADDRESSES: Requests for copies of the patent(s)/patent application(s),
inquiries, comments and other materials relating to the contemplated
exclusive license should be directed to: Jonathan V. Dixon, Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; Telephone: 301.435.5559; Facsimile 301.402.0220; email
dixonj@od.nih.gov.
SUPPLEMENTARY INFORMATION: The above-referenced patent application
relates to the discovery of actin binding peptides that have been shown
to promote hair growth. Specifically the patent application discloses a
seven amino acid peptide of Thymosin-beta4 that promotes hair growth.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within 60 days
from the date of this published notice, the NIH receives written
evidence and argument that establish that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: December 13, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 02-32347 Filed 12-23-02; 8:45 am]
BILLING CODE 4140-01-P